Breast cancer is associated with alterations in a number of growth factor and hormone-regulated signaling pathways. Mouse models of metastatic breast cancer typically feature mutated oncoproteins that activate PI3K, Stat3, and Ras signaling, but the individual and combined roles of these pathways in breast cancer progression are poorly understood. In this study, we examined the relationship between oncogenic pathway activation and breast cancer subtype by analyzing mouse mammary tumor formation in which each pathway was activated singly or pairwise. All three oncogenes showed cooperation during primary tumor formation, but efficient dissemination was only dependent on Ras. In addition, transcriptional profiling demonstrated that Ras induced adenocarcinomas with molecular characteristics related to human basal-like and HER2 þ tumors. In contrast, Ras combined with PIK3CA H1047R , an oncogenic mutant linked to ERa þ /luminal breast cancer in humans, induced metastatic luminal B-like tumors. Consistent with these data, elevated Ras signaling was associated with basal-like and HER2 þ subtype tumors in humans and showed a statistically significant negative association with estrogen receptor (ER) signaling across all breast cancer. Despite this, there are luminal tumors with elevated Ras signaling. Importantly, when considered as a continuous variable, Ras pathway activation was strongly linked to reduced survival of patients with ERa þ disease independent of PI3K or Stat3 activation. Therefore, our studies suggest that Ras activation is a key determinant for dissemination and poor prognosis of ERa þ /luminal breast cancer in humans, and hormone therapy supplemented with Ras-targeting agents may be beneficial for treating this aggressive subtype. Cancer Res; 75(22); 4960-72. Ó2015 AACR.
Introduction
Ras genes are mutated in a relatively small percentage of human breast cancers. However, Ras signaling can be activated through copy number changes or mutation of many genes, including those coding for tyrosine kinase receptors like HER2, as well as genes coding for tyrosine phosphatases, for regulators of Ras-GTP loading or for kinases functioning downstream of Ras. Indeed, 28% of human breast tumors have deletions or loss-of-function mutations in NF1, which codes for a Ras GTPase activating protein (Gap; ref. 1). Other tumors show reduced expression of RASAL2, a distinct RasGap gene. While RASAL2 is not commonly deleted or mutated, reduced expression is associated with luminal B breast cancer (2) .
Ras was first linked to metastatic transformation in fibroblasts (3). Subsequently, a number of mouse models of human breast cancer were generated using activated Ras, and some of these develop metastatic tumors (4, 5) . For example, activated Ras cooperates with loss of Par3 to induce metastatic mammary tumors in mice (6) .
Breast cancer represents a collection of diseases, most of which express the estrogen receptor (ERa). Transcriptional profiling has been used to identify common breast cancer subtypes, including luminal A and luminal B (both of which express ERa), HER2 þ (which express very high levels of HER2/Neu, typically as a result of gene amplification) as well as basal-like and claudin-low tumors (7, 8) . Additional and refined subtypes have been identified through incorporation of data on mutations and copy number alterations (9) and comparison to specific mammary epithelial cell types (10) . These different forms of breast cancer progress through different mechanisms, and poor prognosis in each subtype can be linked to alterations in distinct signaling pathways or transcriptional programs. For example, the "Bach1-pathway metastasis gene signature" (BPMS) is associated with metastasis and poor diseasefree survival of patients with basal-like breast cancer, but not with luminal and HER2 þ tumors (11) .
PIK3CA, which codes for the p110a catalytic subunit of Class I phosphoinositide 3-kinase (PI3K), is the most commonly mutated gene in ERa þ luminal tumors and in metaplastic breast cancer (8, 12) . We recently described the first mouse model for PIK3CA-mutant breast cancer (13) . Most mammary tumors that form in this model are metaplastic adenosquamous carcinomas or adenomyoepitheliomas. Pik3ca H1047R mice do not develop mammary tumors that mimic the much more common ERa þ luminal breast tumor types (13, 14) . While crossing these mice to p53 conditional mutants dramatically enhanced tumor formation, very few luminal type tumors were seen in double mutant animals. Also, the tumors that form in Pik3ca, as well as in Pik3ca/p53 double mutant mice, do not metastasize at a high rate. These data suggest that PIK3CAmutant alleles may cooperate with distinct signaling pathways to induce metastatic ERa þ breast cancer. Muller and colleagues have developed two mouse models for breast cancer, both of which metastasize to lungs (15, 16) . Interestingly, each model involves enhanced Ras signaling (17) . Metastatic dissemination of tumors in MMTV-Neu mice is dependent on Stat3 signaling and can be enhanced through expression of a dominant allele of Stat3 (Stat3 C ; refs. [18] [19] [20] or through deletion of Pten, which activates PI3K signaling (21) .
In an effort to define the relationship between oncogenic pathway activation and breast cancer subtype, as well as metastatic dissemination, we generated mouse models for breast cancer with elevated PI3K, Stat3, and/or Ras signaling. We also used pathway-specific gene signatures to test for linkage of elevated PI3K, Stat3, and Ras to relapse and survival in humans.
Materials and Methods

Mouse colony maintenance
Mice were housed at the Toronto Centre for Phenogenomics and received care according to guidelines defined by the CCAC (Canadian Council on Animal Care). Strains were genotyped using primers listed below. Males were not studied. Genotyping primers used in this work are as follows: (i) for Cre recombinase we used forward primer (FP): 5 0 -TCGCGATTATCTTCTAT-ATCTTCAG-3 0 and reverse primer (RP): 5 0 -GCTCGACCAGT-TTAGTTACCC-3 0 (13), (ii) for R26-Stat3 C we used FP: 5 0 -AAAGTCGCTCTGAGTTGTTAT-3 0 , RP1: 5 0 -GGAGCGGGAGAAA-TGGATATG-3 0 and RP2: 5 0 -GCGAAGAGTTTGTCCTCAACC-3 0 (22), (iii) for R26-Pik3ca H1047R we used FP: 5 0 -AAAGTCGCTCT-GAGTTGTTAT-3 0 , RP1: 5 0 -GGAGCGGGAGAAATGGATATG-3 0 and RP2: 5 0 -GCGAAGAGTTTGTCCTCAACC-3 0 (22), (iv) for K-Ras G12D we used FP: 5 0 -CCATGGCTTGAGTAAGTCTGC-3 0 and RP: 5 0 -CGCAGACTGTAGAGCAGCG-3 0 (23).
Tumor collection
Mice were monitored for onset/progression of neoplastic disease, and humanely sacrificed at endpoint. For mammary tumor bearing mice, part of each tumor (with adjacent normal or hyperplastic mammary gland if possible) was fixed in 10% formalin/PBS (Fisher Scientific HC200-20) and then paraffinembedded. The rest of each tumor was divided into smaller samples with a sterile razor blade, frozen, and transferred to a À80 C freezer for storage.
Molecular subtype classification
Microarray analysis on mouse tumor models was carried out using Affymetrix Mouse Gene 2.0 ST (Centre for Applied Genomics, Hospital for Sick Children, Toronto, Ontario, Canada). The GEO accession number is GSE73073. Microarray data were normalized using RMA method via Partek software and log2-transformed gene expression values were obtained. Published datasets containing multiple mouse models (GSE42640) and human breast cancer subtypes predetermined by PAM50 (GSE18229) were downloaded from the GEO database. Data from our mouse models were integrated with the above GSEs using "Distance Weighted Discrimination" (DWD). Unsupervised hierarchical clustering (complete linkage) with the intrinsic genes signature (24) was used to group tumor samples for subtype classification.
Statistical analysis
Statistical analysis for Kaplan-Meier survival curves was done in R (25) . These curves were generated using the "survival" library and the "survfit" function. Survival statistics were calculated as nonparametric log rank P values for censored survival data using the "survdiff" function (26) . Censored data (represented by "|" on Kaplan-Meier survival curves) represents a mouse that was removed from the study before 18 months. For overall survival, censored mice were removed prematurely from the study for a variety of reasons such as unresolved infections. For mammary tumor-free survival analysis, censored mice were removed prematurely due to any non-mammary tumor endpoint or death. Means and SEs and t tests were also calculated using R. In each case, significant statistical differences were defined as P < 0.05 and tests were run one-sided at a 95% confidence interval.
Histology and immunostaining
Five micron thick paraffin sections were stained with hematoxylin and eosin (H&E) for histology. For immunohistochemistry and immunofluorescence, sections were deparaffinized in xylene and rehydrated through an alcohol series. Antigen retrieval was performed in a digital decloaking chamber (Biocare Medical; Set-Point1 ¼ 125 C for 5 minutes, Set-Point2 ¼ 90 C for 10 seconds), using heat-induced epitope-retrieval solution (Reveal Decloaker pH 6.0, Biocare Medical RV1000G1). Slides were rinsed in running tap water for 5 minutes and then mounted onto a Tecan FreedomEvo liquid-handling robot. Staining was performed according to standard procedures (13, 27) . Images were captured with an AxioCam HRm digital camera (Zeiss) and AxioVision (release 4.6.3) software. Immunocytochemistry images using anti-ERa antibodies (Santa Cruz Biotechnology; Cat# sc-542 at 1:100 dilution) were captured using Velocity software (Perkin-Elmer, release 6.2.1).
Testing for relationship of signaling pathway activation with relapse/survival in breast cancer patients
Patient samples from three independent gene expression datasets (GSE1456, GSE2034 and GSE3494) stored in the GEO database were analyzed as survival information of the samples is available online. The survival information in these datasets include either relapse, death, or both. We first analyzed the disease-free survival (DFS) based on datasets GSE1456 and GSE2034, where survival event is relapse. The combined dataset includes 445 samples and 147 of them relapsed. We them performed overall survival (OS) based on datasets GSE1456 and GSE3494, where survival event is death. The combined dataset . A-C, Kaplan-Meier mammary tumor-free survival curves for control (MMTV-Cre and Cre-negative R26-Pik3ca H1047R , R26-Stat3 C , and K-Ras G12D ) and experimental mice. Six cohorts of MMTV-Cre-positive experimental mice were used: R26-Pik3ca H1047R , R26-Stat3 C , both Pik3ca H1047R and Stat3 C at the R26 locus, K-Ras G12D , R26-Pik3ca H1047R with K-Ras G12D , and R26-Stat3 C with K-Ras includes 410 samples and 84 have died from breast cancer. In both cases, the patients who did not have the event are considered censored. We accessed the pathway activation information for each of the patient samples in PI3K, Stat3, and Ras signaling from Supplementary Table S1 in Gatza and colleagues (28) . The pathway activation is represented as relative probability (0-1). The higher the probability, the more active the pathway in a given sample is. Survival analyses were performed by constructing Kaplan-Meier survival curves for a given pathway, and the log-rank test was used to examine the differences between groups (26). These have been done for high active and low active patients in a given pathway. The high active patients are those that have pathway activation probability larger than or equal to 0.5 while the low active patients are those that have pathway activation probability smaller than 0.5. A Cox proportional hazard regression model (29) was also used to evaluate the association between the survival information and pathway activation for each of the candidate pathways, where pathway activation has not been binarized and was treated as a continuous variable. We performed the analyses using Survival R package (25) .
Testing for relationship of combinations of signaling pathway activation with relapse/survival in breast cancer patients
For a combination of two or three pathways among PI3K, Stat3, and Ras, high active patients are those that have pathway active probability larger than or equal to 0.5 in the combination while low active patients are those that have pathway active probability smaller than 0.5 in either PI3K, Stat3, or Ras pathway. Survival analyses were performed by constructing Kaplan-Meier survival curves for the combination of pathways given the defined high and low active patients.
Results
Ras cooperates with mutant/activated Pik3ca or Stat3 to induce ERa þ mammary tumors
As transformation by mutant PIK3CA can be dependent on tyrosine phosphorylation of Stat3 (30) , and activated Stat3 is associated with metastatic dissemination in some contexts (18) (19) (20) , we tested for cooperation between Pik3ca H1047R and Stat3 A661C/N663C (31). This allele, commonly known as Stat3 C , produces a mutant protein with prolonged activity in response to Y705 phosphorylation, and induces elevated expression of Stat3 target genes. Both effects are linked to a slower rate of Stat3 C dephosphorylation in the nucleus, as well as to increased DNA binding affinity (32) (33) (34) . The R26 Cre-conditional transgenic system has been used to express Pik3ca H1047R (13) and Stat3 C (35, 36) . We therefore intercrossed these lines to link induction of both alleles to expression of Cre recombinase. Specifically, we compared mammary tumor formation in female mice from the following cohorts: (i) R26-Pik3ca H1047R ;MMTV-Cre NLST , (ii) R26-Pik3ca H1047R /Stat3 C ;MMTV-Cre NLST , (iii) R26-Stat3 C ;MMTV-Cre NLST , and (iv) negative controls (including transgenics without Cre as well as MMTV-Cre NLST only mice). No statistically significant difference in tumor formation was seen between mice in double and triple transgenics (cohorts i and ii, respectively; Fig.  1A ; Supplementary Table S1 ). Also, mammary tumors that formed in R26-Pik3ca H1047R ;MMTV-Cre NLST and R26-Pik3ca H1047R /Stat3 C ;MMTV-Cre NLST mice were mostly either adenomyoepitheliomas or adenosquamous carcinomas, and the ratio of major tumor types was not affected by expression of Stat3 C (Fig.  1E and F). Finally, overall survival, cause of death, and number of mammary tumors per mouse were also unaffected by expression of Stat3 C in Pik3ca model mice ( Fig. 1D and Supplementary Fig.  S1A and B and Supplementary Table S1 ).
p21 Ras activation is linked to induction of mammary tumors with luminal features (17) and to metastatic dissemination (3). We therefore tested whether Cre-inducible K-Ras G12D (23) would cooperate with Pik3ca H1047R to induce mammary tumors. To this end, we analyzed mammary tumor formation in female mice from the following cohorts: (1) K-Ras G12D ;MMTV-Cre NLST , (2) K-Ras G12D ;R26-Pik3ca H1047R ; MMTV-Cre NLST , (3) R26-Pik3ca H1047R ;MMTV-Cre NLST , and (4) negative controls. Cohort 3 represents the same mice as described above. Mammary tumor-free and overall survival were dramatically decreased in both K-Ras mutant cohorts (1 and 2) in comparison with control cohort mice (4) and in comparison with the Pik3ca H1047R ;MMTV-Cre NLST cohort 3 ( Fig.  1B ; Supplementary Fig. S1A and Supplementary Table S1 ). Also, K-Ras G12D ;R26-Pik3ca H1047R ;MMTV-Cre NLST mice showed decreased mammary tumor-free and overall survival in comparison with K-Ras G12D ; MMTV-Cre NLST cohort mice, demonstrating cooperation between K-Ras G12D and Pik3ca H1047R . Cooperation between K-Ras G12D and Pik3ca H1047R did not translate to an increase in mammary tumors per mouse (Fig.  1D ). In comparison with Pik3ca model mice, which developed mostly keratinized tumors (such as adenosquamous carcinomas) and adenomyoepitheliomas ( Fig. 1E ), Ras model mice (K-Ras G12D alone, or K-Ras G12D þ Pik3ca H1047R ) developed adenocarcinomas [such as poorly differentiated adenocarcinoma (PDA) or complex adenocarcinoma, which contain multiple histologies (CAC)] at a high frequency (Figs. 1G and H, and 2A and B; ref. 17) .
We next tested for cooperation between K-Ras G12D and activated Stat3 (Stat3 C ). As noted above, R26-Stat3 C ;MMTV-Cre NLST mice did not develop mammary tumors ( Fig. 1A/C ). However, when K-Ras G12D and Stat3 C were expressed together, overall survival and mammary tumor-free survival were significantly reduced in comparison with mice expressing K-Ras G12D by itself (Continued.) Analysis was based on observational data collected at necropsy. E-I, mammary tumors from R26-Pik3ca H1047R ;MMTV-Cre mice (E) were mostly adenosquamous carcinomas (ASC) or adenomyoepitheliomas (AME). A smaller number of tumors were squamous cysts (SC), poorly differentiated adenocarcinomas (PDA), papillary adenocarcinomas (Pap), complex adenocarcinomas (CAC), scirrhous tumors/radial scars (ST/RS) or scirrhous tubular carcinomas (STC and R26-Stat3 C were expressed together (I), mice developed many poorly differentiated adenocarcinomas, complex adenocarcinomas, and scirrhous tubular carcinomas, suggesting expression of mutant K-Ras determines mammary tumor pathology. A smaller number of acinar tumors, adenosquamous carcinomas, squamous cysts, squamous cell carcinomas, keratoacanthomas, solid nodular carcinomas, and adenomyoepitheliomas also formed.
( Fig. 1C and Supplementary Fig. S1A ; Supplementary Table S1 ). Once again, cooperation was not seen at the level of mammary tumors per mouse (Fig. 1D ). As with other Ras models (K-Ras G12D alone, or K-Ras G12D with Pik3ca H1047R ), K-Ras G12D ;R26-Stat3 C ; MMTV-Cre NLST mice developed adenocarcinomas at a high frequency (Figs. 1C and I and 2C). As all models with mutant Ras developed PDAs and CACs, we tested for estrogen receptor (ERa) expression in these lesions. Indeed, the majority of tumors that formed in K-Ras G12D alone, K-Ras G12D plus Pik3ca H1047R and K-Ras G12D plus Stat3 C cohorts were ERa þ ( Fig. 2A-D ; Supplementary Fig 2) . Interestingly, these tumors stained positive for Stat3 pY705 and express phospho-MapK ( Supplementary Figs.  S3A and S3B) , which is consistent with findings in mammary tumors from MMTV-Ras mice (37) . Thus, either oncogenic Ras or oncogenic events that cooperate with Ras, activate Stat3 phosphorylation in this context.
Luminal oncogene, Pik3ca H1047R , shifts the effect of Ras towards luminal B subtype tumors
Gene expression profiling has been used to analyze mouse models of breast cancer. Indeed, when 27 models were analyzed, they partitioned into 17 distinct molecular subtypes with characteristic relationships to major human subtypes (38) . For example, tumors from our R26-Pik3ca H1047R ; MMTV-Cre NLST model were mostly adenomyoepitheliomas with a Class14 Ex signature or adenosquamous carcinomas with a Squamous-like Ex signature (38) . In contrast, tumors with activated Ras had Neu Ex or Class8 Ex signatures (4, 38) , with similarity to luminal A breast cancer in humans and with features related to normal alveolar function. Mammary tumors from K-Ras G12D ; MMTV-Cre NLST mice formed adenocarcinomas with some squamous differentiation. These clustered near Pik3ca H1047 tumors with a Squamous-like Ex signature ( Fig. 3 ). In comparison with human molecular subtypes, they clustered near normal human breast cancers but within the HER2 subtype ( Fig. 4 ). Most strikingly, when activated K-Ras G12D and Pik3ca H1047R were combined, the mammary tumors that formed had a distinct gene expression signature, with a high degree of similarity to luminal B breast cancer. Thus, Ras and PI3K pathways cooperate to induce luminal B type tumors. Mammary tumors that form in Pik3ca H1047R mice had a very low rate of lung metastasis (3/51 mice had one or two mets each, see Fig. 5A ). Given the published link between Stat3 and metastasis (18, 19) , we also screened tumor bearing mice from Pik3ca H1047R ;Stat3 C transgenics for disseminated disease. Metastases occurred in a small percentage of tumor bearing R26-Pik3ca H1047R /Stat3 C ;MMTV-Cre NLST triple transgenics (mets detected in 24% or 5/21 mice; Fig. 5A ). Once again, one or two small metastatic lesions were found in these mice. Finally, we screened Ras cohorts for metastasis. Indeed, half of Ras-alone mammary tumor-bearing mice had lung metastases (7/14; Fig. 5A and B). 44% (11/25) of K-Ras G12D þ Pik3ca H1047R tumor bearing mice and 58% (11/19) of K-Ras G12D þ Stat3 C tumor bearing mice had metastasis ( Fig. 5A and B) . Twenty percent and 32% of tumor-bearing mice from each Ras-expressing/double-oncogene cohort (K-Ras G12D /Pik3ca H1047R and K-Ras G12D /Stat3 C , respectively) had greater than 10 lung metastases ( Fig. 5A and  B) . Thus, activated Ras can cooperate with a Pik3ca mutant or activated Stat3 to induce transformation, as well as metastatic dissemination of tumor cells. However, as noted above, Ras-alone tumors were also metastatic. Next, histology was compared between lung metastases and primary tumors from the same animals. In 4 of 5 K-Ras G12D ;MMTV-Cre mice analyzed, the histology of lung metastases matched the histology of mammary tumors from the same mouse (both were poorly differentiated adenocarcinomas or PDA). In one case, lung metastases were PDA, whereas mammary tumors in this mouse were squamous cyst and keratoacanthoma. In 5 of 5 R26-Pik3ca H1047R ; K-Ras G12D ; MMTV-Cre mice, lung metastases histology matched that of mammary tumors from the same mouse (2 were PDA and 3 were a mix of PDA and spindle cell tumors or SCT). Finally, in 3 of 3 R26-Stat3 C ;K-Ras G12D ;MMTV-Cre mice, lung metastases histology matched mammary tumors from the same mouse (2 were PDA and 1 was SCT).
High-level Ras signaling is associated with relapse and death of luminal breast cancer patients
Gatza and colleagues have reported on gene expression signatures associated with activation of 18 different signaling pathways in human breast cancer (28) . To establish these signatures, they infected cells with adenoviral vectors expressing pathway activating signaling proteins and used transcriptional profiling to find genes that were induced or repressed in response to each pathway (see Supplementary Data in Gatza and colleagues; ref. 28) . To test for an effect of PI3K, Stat3, and Ras signaling on breast cancer relapse and death, we tested for activation of these pathways in publicly available gene expression datasets with linked follow-up data. Indeed, Ras pathway activation was associated with a significant increase in relapse [HR, 2.0; 95% confidence interval (CI), 1.4-2.8; P ¼ 2.3 Â 10 À5 ; Fig. 6A ). Also, high level Ras signaling showed a significant association with increased chance of death (HR, 2.5; 95% CI, 1.6-3.9; P ¼ 1.9 Â 10 À5 ; Fig. 6B ). As for high PI3K or Stat3 signaling, we did not see a significant correlation with relapse ( Fig. 6A) or death (Fig. 6B) for either pathway. Linkage of Ras activation to PI3K or Stat3 pathway activation did not enhance the affect of Ras ( Supplementary Fig. S4 ). Similar, but much more dramatic results were obtained if we treated pathway activation information as a continuous variable in a multivariate Cox proportional hazard regression model (Table 1A and B; for relapse: HR ¼ 8.2, 95% CI, 2.9-24; P ¼ 8.4 Â 10 À5 ; for survival: HR, 22.4; 95% CI, 5.4-93; P ¼ 1.8 Â 10 À5 ).
Next, we tested for effects of PI3K, Stat3, or Ras signaling on relapse or death within each molecular subtype. Previous transcriptional profiling showed an association between elevated Ras signaling and basal-like as well as HER2 þ subtypes (28) . Consistent with these findings, we saw a negative correlation between ER pathway activity and Ras signaling (activity correlation -0.44, Wilcox test P ¼ 9.3 Â 10 À11 ). With respect to patient outcome, elevated PI3K signaling was found to be associated with relapse in basal-like breast cancer (HR, 2.50; 95% CI, 1.0 -6.3; P ¼ 0.044), but not in HER2 þ , luminal (A or B), or normal breast cancer subtypes. It was not associated with death in any cancer subtype ( Supplementary Fig. S5 ). Stat3 pathway activation was also not associated with relapse or death in any subtype ( Supplementary  Fig. S5 ). In contrast, Ras pathway activation was linked to relapse, specifically in patients with luminal A (HR, 2.7; 95% CI, 1.1-6.4; P ¼ 0.024) and luminal B (HR, 1.9; 95% CI, 1.3-3.0; P ¼ 0.0026) subtype tumors (Fig. 6C ). It was also associated with death in luminal B breast cancer (HR, 2.5; 95% CI, 1.4-4.5, P ¼ 0.0016; Fig.  6D ). Subtype analysis is based on binarization of pathway activation data. These relatively small effects are consistent with the previously identified link between high Ras pathway activation and poor survival when activation of pRaf and pMapk were assessed in ERa þ breast cancer (39) .
Once again, similar but much more dramatic results were obtained if we treated pathway activation data as a continuous variable in a Cox proportional hazard regression model. In this case, PI3K pathway activation showed a significant association 
Discussion
The metastatic process involves many steps, starting with primary tumor cell invasion, followed by neoangiogenesis and intravasation into small blood or lymphatic vessels. Alternatively, access to blood vessels can be associated with vascular mimicry (40) . Within the circulation, a metastatic tumor cell or clump of cells must survive as it travels to another organ or tissue (41, 42) . At secondary sites, a tumor cell must extravasate out of the vasculature and into the surrounding tissue. These events often involve an epithelial to mesenchymal transition, which may have to be reversed as cells establish secondary lesions (43) . Finally, after a variable period of dormancy, micrometastases must survive and grow to form secondary lesions (44) (45) (46) (47) (48) (49) . Cells within a primary tumor have evolved and adapted to grow under very specific conditions. However, if these cells enter the circulation and travel to another tissue, many of the signals required for growth and/or survival may not be present at the new site. Strikingly, elevated Ras signaling can, in the right context, promote all of these steps. For example, Ras can activate EMT, cellular invasion, motility, survival, angiogenesis, and even altered metabolism (50) (51) (52) . In the context of ER þ breast tumor metastasis, it is unclear which of these are enhanced by Ras.
Advanced breast tumors can metastasize to the lung, liver, bone, and brain. Additional genetic or epigenetic alterations may be required for breast cancer cells to home to these sites and then to grow within a new environment. Over the past decade, the Massagu e lab have used mouse models to investigate these phenomena and subsequently reported on a number of molecular properties associated with dissemination of breast cancer to specific organs (53) (54) (55) . For example, metastasis to bone is associated with elevated Src tyrosine kinase activity (56, 57) . Other studies have highlighted the importance of an IL6/IL11 signal to Stat3 in metastatic dissemination of breast cancer to the bone, as well as Jagged1/Notch, Rankl/Rank signaling, and suppression of interferon signaling (58) . Many of the screens for signaling pathways involved in site-specific metastatic dissemination have been performed on MDA-MB-231 cells, a high metastatic cell line with activated K-Ras (59) . Thus, the importance of Ras signaling in metastatic dissemination to many tissues has not been tested directly.
The connection between Ras signaling and metastasis was discovered over 25 years ago (3) . While Ras genes are not commonly mutated in human breast cancer, this pathway is activated downstream of tyrosine kinase receptors (28, 60) . In addition, GTP loading of p21 Ras occurs in response to loss-of-function mutations or reduced expression of Ras GTPase activating proteins (GAP), like NF1 or Rasal2 (1, 2). Ras is activated downstream of Polyoma Middle T and Her2/Neu in mouse models of metastatic breast cancer (15, 16) . In each case, Ras is activated together with PI3K and Stat3. We therefore studied these pathways individually and in pairs, in an effort to test for cooperation as well as for the role of each pathway in mammary tumor type and dissemination. PIK3CA is the most commonly mutated gene in human luminal-subtype breast cancers, but Pik3ca models develop mostly keratinized tumors (such as adenosquamous carcinomas) and adenomyoepitheliomas with similarity to "normal-like" tumors in humans (38) . Also, as noted above, Neu Ex and Class8 Ex mammary tumors developed in MMTV-H-Ras mice (4, 38) . These signatures have similarity to luminal A and normal-like breast cancer in humans, respectively. The K-Ras model studied here formed mammary tumors with a more squamous gene expression profile (Fig. 3) , and similarity to HER2 þ subtype tumors in humans. Remarkably, when activated Ras and Pik3ca were expressed together, metastatic luminal B-like mammary tumors formed. Thus, elevated Ras signaling promotes formation of metastatic mammary tumors in mice and, when expressed with the luminal-associated oncogene, Pik3ca H1047R , establishes a reproducible model for ERa þ /luminal B breast cancer.
To study the importance of PI3K, Stat3, and Ras signaling on relapse and survival in humans with breast cancer, we used pathway-specific signatures to analyze publicly available gene expression from cohorts with linked outcome data (28) . Importantly, the Ras signature described by Gatza and colleagues was developed in human mammary epithelial cells infected with an H-Ras-expressing adenovirus and validated against colon cancer samples with known K-Ras mutational status (28) . This signature is activated in many human breast cancers particularly in basal-like and HER2 þ tumors (28, 61) . Importantly, then, the signature identifies breast tumors with high Ras signaling, despite the absence of Ras gene mutations in this disease. In addition, this signature does not discriminate between H-Ras and K-Ras signaling, and it is biased towards genes that are expressed in mammary epithelium. Using this signature, we found a strong relationship between Ras pathway activation and relapse, as well as reduced survival for patients with luminal A and B subtype disease. This effect was not enhanced when we tested for tumors with high levels of signaling through Ras and PI3K pathways, or through Ras and Stat3 pathways. Importantly, the effect of Ras was particularly strong when pathway activity was considered as a continuous variable, suggesting that p21 Ras -GTP may well promote metastasis in a concentration-dependent manner. Such a dose-dependent effect would also explain why mutation of Rasal2 enhanced metastatic dissemination and outgrowth in MMTV-Neu mice, a model that is already metastatic (2) .
On the basis of published work with MCF7 cells (62, 63) , where oncogenic Ras makes this line estrogen independent, as well as on the fact that high Ras signaling as a binary variable is associated with poor prognosis for ERa þ breast cancer patients treated with tamoxifen (39), it seems likely that hormonal therapy would prove ineffective in our Pik3ca/Ras mouse model of luminal B-like breast cancer. However, this model could be exploited to screen for novel therapeutics to treat hormone therapy-resistant tumors. Also, given that Ras signaling functions as a continuous variable, it may be worth combining Ras pathway-targeted therapeutics, like Mek inhibitors, together with hormone therapy, even for luminal breast cancer patients with relatively low pathway signaling. Finally, as Ras pathway signaling can sensitize cells to chemotherapy, perhaps Ras and ERa pathways could be targeted sequentially.
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